SAGE THERAPEUTICS INC (SAGE) Stock Fundamental Analysis
USA - NASDAQ:SAGE - US78667J1088 - Common Stock
8.68 USD
-0.02 (-0.23%)
8.685 USD
+0.01 (+0.06%)
We assign a fundamental rating of 3 out of 10 to SAGE. SAGE was compared to 533 industry peers in the Biotechnology industry. While SAGE seems to be doing ok healthwise, there are quite some concerns on its profitability. SAGE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SAGE has reported negative net income.
In the past year SAGE has reported a negative cash flow from operations.
SAGE had negative earnings in 4 of the past 5 years.
SAGE had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of SAGE (-71.22%) is worse than 64.07% of its industry peers.
SAGE has a Return On Equity of -81.68%. This is comparable to the rest of the industry: SAGE outperforms 50.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.22% | ||
| ROE | -81.68% | ||
| ROIC | N/A |
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of SAGE (45.16%) is better than 75.50% of its industry peers.
SAGE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SAGE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.16% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
2. Health
2.1 Basic Checks
SAGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SAGE has been increased compared to 1 year ago.
Compared to 5 years ago, SAGE has more shares outstanding
There is no outstanding debt for SAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -5.35, we must say that SAGE is in the distress zone and has some risk of bankruptcy.
SAGE's Altman-Z score of -5.35 is on the low side compared to the rest of the industry. SAGE is outperformed by 61.52% of its industry peers.
SAGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.35 |
ROIC/WACCN/A
WACC11.13%
2.3 Liquidity
SAGE has a Current Ratio of 9.16. This indicates that SAGE is financially healthy and has no problem in meeting its short term obligations.
SAGE has a better Current ratio (9.16) than 75.32% of its industry peers.
A Quick Ratio of 9.16 indicates that SAGE has no problem at all paying its short term obligations.
SAGE has a better Quick ratio (9.16) than 75.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.16 | ||
| Quick Ratio | 9.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 43.60% over the past year.
The Revenue for SAGE has decreased by -27.58% in the past year. This is quite bad
Measured over the past years, SAGE shows a very strong growth in Revenue. The Revenue has been growing by 42.99% on average per year.
EPS 1Y (TTM)43.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.53%
Revenue 1Y (TTM)-27.58%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%265.84%
3.2 Future
The Earnings Per Share is expected to grow by 13.71% on average over the next years. This is quite good.
Based on estimates for the next years, SAGE will show a very strong growth in Revenue. The Revenue will grow by 40.01% on average per year.
EPS Next Y44.26%
EPS Next 2Y24.68%
EPS Next 3Y19.27%
EPS Next 5Y13.71%
Revenue Next Year93.34%
Revenue Next 2Y66.24%
Revenue Next 3Y54.03%
Revenue Next 5Y40.01%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SAGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAGE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SAGE's earnings are expected to grow with 19.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.68%
EPS Next 3Y19.27%
5. Dividend
5.1 Amount
No dividends for SAGE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.68
-0.02 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners80.99%
Inst Owner Change-97.93%
Ins Owners0.25%
Ins Owner Change-56.38%
Market Cap543.54M
Revenue(TTM)70.41M
Net Income(TTM)-301.19M
Analysts69.41
Price Target8.67 (-0.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.48%
Min EPS beat(2)0.49%
Max EPS beat(2)18.46%
EPS beat(4)3
Avg EPS beat(4)4.88%
Min EPS beat(4)-1.61%
Max EPS beat(4)18.46%
EPS beat(8)3
Avg EPS beat(8)-5.91%
EPS beat(12)4
Avg EPS beat(12)-4.23%
EPS beat(16)7
Avg EPS beat(16)-3.76%
Revenue beat(2)1
Avg Revenue beat(2)41.33%
Min Revenue beat(2)-2.5%
Max Revenue beat(2)85.16%
Revenue beat(4)2
Avg Revenue beat(4)19.35%
Min Revenue beat(4)-12.99%
Max Revenue beat(4)85.16%
Revenue beat(8)4
Avg Revenue beat(8)11.31%
Revenue beat(12)7
Avg Revenue beat(12)12.94%
Revenue beat(16)7
Avg Revenue beat(16)2.33%
PT rev (1m)-1.66%
PT rev (3m)5.63%
EPS NQ rev (1m)1.96%
EPS NQ rev (3m)-0.7%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.57%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)2.68%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.72 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.47 | ||
| P/tB | 1.47 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.89
EYN/A
EPS(NY)-2.94
Fwd EYN/A
FCF(TTM)-4.62
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS1.12
BVpS5.89
TBVpS5.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -71.22% | ||
| ROE | -81.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.16% | ||
| FCFM | N/A |
ROA(3y)-57.96%
ROA(5y)-34.18%
ROE(3y)-65.47%
ROE(5y)-38.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.74%
GM growth 5Y-3.93%
F-Score3
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.16 | ||
| Quick Ratio | 9.16 | ||
| Altman-Z | -5.35 |
F-Score3
WACC11.13%
ROIC/WACCN/A
Cap/Depr(3y)40.51%
Cap/Depr(5y)28.52%
Cap/Sales(3y)4.11%
Cap/Sales(5y)3.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.53%
EPS Next Y44.26%
EPS Next 2Y24.68%
EPS Next 3Y19.27%
EPS Next 5Y13.71%
Revenue 1Y (TTM)-27.58%
Revenue growth 3Y87.07%
Revenue growth 5Y42.99%
Sales Q2Q%265.84%
Revenue Next Year93.34%
Revenue Next 2Y66.24%
Revenue Next 3Y54.03%
Revenue Next 5Y40.01%
EBIT growth 1Y32.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.48%
EBIT Next 3Y19.55%
EBIT Next 5Y14.35%
FCF growth 1Y45.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.51%
OCF growth 3YN/A
OCF growth 5YN/A
SAGE THERAPEUTICS INC / SAGE FAQ
Can you provide the ChartMill fundamental rating for SAGE THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 3 / 10 to SAGE.
Can you provide the valuation status for SAGE THERAPEUTICS INC?
ChartMill assigns a valuation rating of 0 / 10 to SAGE THERAPEUTICS INC (SAGE). This can be considered as Overvalued.
Can you provide the profitability details for SAGE THERAPEUTICS INC?
SAGE THERAPEUTICS INC (SAGE) has a profitability rating of 1 / 10.
How financially healthy is SAGE THERAPEUTICS INC?
The financial health rating of SAGE THERAPEUTICS INC (SAGE) is 6 / 10.